Han Y - Search Results

1

Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.

Deng T, Zhang L, Liu XJ, Xu JM, Bai YX, Wang Y, Han Y, Li YH, Ba Y. Deng T, et al. Among authors: han y. Med Oncol. 2013 Dec;30(4):752. doi: 10.1007/s12032-013-0752-z. Epub 2013 Oct 31. Med Oncol. 2013. PMID: 24174316 Clinical Trial.

2

Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.

Xu JM, Han Y, Li YM, Zhao CH, Wang Y, Paradiso A. Xu JM, et al. Among authors: han y. BMC Cancer. 2006 Dec 16;6:288. doi: 10.1186/1471-2407-6-288. BMC Cancer. 2006. PMID: 17173694 Free PMC article. Clinical Trial.

3

[Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].

Xu JM, Li YM, Wang Y, Zhao CH, Yuan SJ, Yang WW, Li ZQ, Han Y, Azzariti A, Paradiso A. Xu JM, et al. Among authors: han y. Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):578-82. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17236550 Chinese.

4

[Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].

Xu JM, Li YM, Liu XQ, Zhang Y, Han Y, Yang WW, Song ST. Xu JM, et al. Among authors: han y. Zhonghua Zhong Liu Za Zhi. 2007 Jan;29(1):66-9. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 17575699 Clinical Trial. Chinese.

5

[EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer].

Han Y, Xu JM, Duan HQ, Song ST, Liu XQ, Zhang Y, Zhang JS. Han Y, et al. Zhonghua Zhong Liu Za Zhi. 2007 Apr;29(4):278-83. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 17760255 Chinese.

6

[Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].

Han Y, Xu JM, Duan HQ, Zhang Y, Liu XQ, Zhang JS. Han Y, et al. Chin J Cancer. 2010 Jan;29(1):69-75. doi: 10.5732/cjc.009.10345. Chin J Cancer. 2010. PMID: 20038315 Free article. Chinese.

7

The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines.

Yuan HH, Han Y, Bian WX, Liu L, Bai YX. Yuan HH, et al. Among authors: han y. Pathology. 2012 Oct;44(6):547-51. doi: 10.1097/PAT.0b013e32835817a2. Pathology. 2012. PMID: 22935976

8

Initiation of apoptosis, cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisinin.

Du XX, Li YJ, Wu CL, Zhou JH, Han Y, Sui H, Wei XL, Liu L, Huang P, Yuan HH, Zhang TT, Zhang WJ, Xie R, Lang XH, Jia DX, Bai YX. Du XX, et al. Among authors: han y. Biomed Pharmacother. 2013 Jun;67(5):417-24. doi: 10.1016/j.biopha.2013.01.013. Epub 2013 Feb 19. Biomed Pharmacother. 2013. PMID: 23582790

9

Homocysteine induces procoagulant activity of red blood cells via phosphatidylserine exposure and microparticles generation.

Xie R, Jia D, Gao C, Zhou J, Sui H, Wei X, Zhang T, Han Y, Shi J, Bai Y. Xie R, et al. Among authors: han y. Amino Acids. 2014 Aug;46(8):1997-2004. doi: 10.1007/s00726-014-1755-6. Epub 2014 May 11. Amino Acids. 2014. PMID: 24817414

10

UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution.

Han Y, Yang YN, Yuan HH, Zhang TT, Sui H, Wei XL, Liu L, Huang P, Zhang WJ, Bai YX. Han Y, et al. Pathology. 2014 Aug;46(5):396-401. doi: 10.1097/PAT.0000000000000125. Pathology. 2014. PMID: 24977734

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28,302 results

Search Page

Filters